Targeted therapy is a new cancer treatment approach, involving drugs that particularly target
specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are …

Background and objective Sintilimab is a selective PD-1 inhibitor with efficacy in advanced
or metastatic nonsquamous non-small-cell lung cancer (NSCLC) patients. This study …

Introduction Although tyrosine kinase inhibitors (TKIs) have improved the efficacy of
treatment for non-small cell lung cancer (NSCLC), the accessibility of TKIs is limited due to …

Aim To evaluate the cost-effectiveness of first-line treatments, such as erlotinib, gefitinib,
afatinib, dacomitinib, and osimertinib, for patients diagnosed with stage IIIB/IV NSCLC …

Purpose In 2013, afatinib was approved for non–small-cell lung cancer with subsequent
indication expansion. We investigated published afatinib clinical trials to assess risk and …

Targeted therapy is a new cancer treatment approach, involving drugs that particularly target
specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are …

Tóm tắt Mục tiêu: Đánh giá tính chi phí hiệu quả của Afatinib so với Gefitinib và Erlotinib
trong điều trị ung thư phổi không tế bào nhỏ có đột biến EGFR tại Việt Nam. Phương pháp …

Afatinib is the most cost-effective option as first-line treatment for patients with advanced non-
small-cell lung cancer (NSCLC) harbouring an epidermal growth factor receptor (EGFR) …